Through the looking glass: The protein science of biosimilars

被引：9

作者：

Goldsmith D. ^{[1
]}

Kuhlmann M. ^{[2
]}

Covic A. ^{[3
]}

机构：

[1] Renal Unit, New Guy House, Guy's Hospital, London

[2] Vivantes Klinikum Im Friedrichshain, Berlin

[3] C.I. Parhon University Hospital, Iasi

来源：

Clinical and Experimental Nephrology | 2007年 / 11卷 / 3期

关键词：

Assays; Biopharmaceuticals; Biosimilars; Glycosylation; Manufacturing; Pharmacovigilance;

D O I：

10.1007/s10157-007-0487-2

中图分类号：

学科分类号：

摘要：

Biopharmaceuticals have revolutionized the treatment and management of many diseases. The advent of recombinant erythropoietins has greatly benefited patients with anemia related to chronic kidney disease and cancer, virtually eliminating the need for blood transfusions. Currently, the patents for many biopharmaceutical molecules have expired or are approaching expiration and a number of biosimilars manufacturers are aiming to claim part of the market share. Unlike the situation for synthetic "small molecule" drugs, identical copies of far more complex biopharmaceuticals cannot be produced. A biopharmaceutical can be 100 to 1000 times larger than a synthetic chemical drug, with extremely complex three-dimensional structure and biological functions which are often not completely understood. Due to their nature and complexity, these fascinating therapeutic molecules are products of highly controlled biological processes. This review takes a look at how biosimilars are fundamentally different from their originator products by examining the biopharmaceutical production process and how it can influence the structure and function of the final drug product. © 2007 Japanese Society of Nephrology.

引用

页码：191 / 195

页数：4

共 40 条

[1]

Guidelines on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins As Active Substance: Quality Issues, (2005)

[2]

The Biotech Industry's Views on the Pharma Review Package

[3]

Schellekens H., Biosimilar therapeutic agents: Issues with bioequivalence and immunogenicity, Eur J Clin Invest, 34, pp. 797-9, (2004)

[4]

Walsh G., Jefferis R., Post-translational modifications in the context of therapeutic proteins, Nat Biotechnol, 24, pp. 1241-52, (2006)

[5]

Gerngross T.U., Advances in the production of human therapeutic proteins in yeasts and filamentous fungi, Nat Biotechnol, 22, pp. 1409-14, (2004)

[6]

Elliott S., Egrie J., Browne J., Lorenzini T., Busse L., Rogers N., Et al., Control of rHuEPO biological activity: The role of carbohydrate, Exp Hematol, 32, pp. 1146-55, (2004)

[7]

Sylvester R.K., Clinical applications of colony-stimulating factors: A historical perspective, Am J Health Syst Pharm, 59, pp. 6-12, (2002)

[8]

Raju T.S., Briggs J.B., Borge S.M., Jones A.J., Species-specific variation in glycosylation of IgG: Evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics, Glycobiology, 10, pp. 477-86, (2000)

[9]

Misaizu T., Matsuki S., Strickland T.W., Takeuchi M., Kobata A., Takasaki S., Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin, Blood, 86, pp. 4097-104, (1995)

[10]

Bendig M.M., The production of foreign proteins in mammalian cells, Genet Eng, pp. 91-127, (1988)

← 1 2 3 4 →